CMD22 Capital Markets Day
11
Commercial execution and innovation
NASH and Alzheimer's disease
AD patient journey is complex and underscores key barriers to
overcome for Novo Nordisk to be successful
Million
Significant and growing
unmet need
Hurdles
80
60
Novo Nordisk®
Y
Early symptoms
dismissed as normal
ageing
Complex tests and
limited screening/
diagnosing skills
Lack of prognostic
markers and simple
tests
No DMT
options
Few patients
AD
receiving
diagnosis
40
prevalence
20
20
•
Support healthcare
system preparedness
Larger number of AD patients
expected to enter the system
May lead to significant bottle-
necks and delay to patient care
Market preparation priorities
Increase diagnosis rate
Support NITs development, e.g.
blood-based/digital biomarkers
Increase AD education and
access to screening tools for
PCPs and HCP insight
0
Prevalence Diagnosed
patients
■ МСІ
Eligible
patients
Mild dementia
Note: MCI and Mild dementia in the graph are both due to AD.
AD: Alzheimer's disease; QD: Once-daily; MCI: mild cognitive impairment; DMT: Disease-modifying treatment; PCP: primary care physicians; NITs: Non-invasive diagnostics; HCP: Healthcare professional
Source: Alzheimer's Association report: 2020 Alzheimer's disease facts and figures, 2020 (16:391-460)
Indicates expected invesment level
•
Evidence generation
Evidence to better understand the
impact of delaying disease
progression
role of neuroinflammation
in disease progression
CMD22
CAPITAL MARKETS DAYView entire presentation